Breaking News
Nelson Fernandes, CerTest Biotec, on Diagnostic Products
We caught up with Nelson Fernandes, the Managing Director at CerTest Biotec, at 33rd ECCMID as he discusses his company’s diagnostic and molecular biology products. He explains that CerTest Biotec specializes in the development of rapid diagnostic tests for infectious diseases, including COVID-19.
Fernandes highlights some of the company’s other key products, such as CerTec’s raw materials and Pharma products.
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more
Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International and the INADcure Foundation, a nonprofit organization whose mission is to […]
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas
Genmab has announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell […]
Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
Quell Therapeutics, a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions […]
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
Astellas Pharma and Kate Therapeutics have announced an exclusive license agreement to develop and commercialize KT430. […]
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals and CRISPR Therapeutics today announced that the United States Food and Drug Administration (FDA) […]
Sir Richard Roberts Elected to National Academy of Sciences
New England Biolabs (NEB®) has announced that Sir Richard Roberts, Nobel Prize winner and Chief […]
Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International and the INADcure Foundation, a nonprofit organization whose mission is to […]
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas
Genmab has announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell […]
Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
Quell Therapeutics, a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions […]
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
Astellas Pharma and Kate Therapeutics have announced an exclusive license agreement to develop and commercialize KT430. […]
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals and CRISPR Therapeutics today announced that the United States Food and Drug Administration (FDA) […]
Sir Richard Roberts Elected to National Academy of Sciences
New England Biolabs (NEB®) has announced that Sir Richard Roberts, Nobel Prize winner and Chief […]